ROSEN, SKILLED INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline.
SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the West class action, go to https://rosenlegal.com/submit-form/?case_id=39367 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the West class action, go to https://rosenlegal.com/submit-form/?case_id=39367, call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255496
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Why IONQ, RGTI and QBTS are Worth the Risk in Quantum Computing
Quantum computing stocks are high-risk, high-reward plays, where the tech still feels futuristic, but the potential upside could be transformative for your portfolio. While giants like NVIDIA (NVDA) and Alphabet (GOOGL) have stakes in the field, pure-play names like IonQ (IONQ), Rigetti Computing (RGTI), and D-Wave Quantum (QBTS) are gaining serious traction. Confident Investing Starts Here: Each is taking a distinct approach in a sector expected to grow significantly over the next decade. With quantum tech reaching what Nvidia's Jensen Huang recently called an 'inflection point,' these companies are riding a powerful wave of both investor excitement and tangible technological progress. IonQ (NYSE:IONQ) | The Trapped-Ion Powerhouse IonQ is shaping up to be the quarterback of the quantum computing world—everyone's watching, and for good reason. Their trapped-ion technology, which uses charged atoms suspended in electromagnetic fields, produces qubits with exceptional coherence times, translating to more stable and reliable calculations. They've already surpassed 100 qubits, and their systems are available across Amazon (AMZN), Microsoft (MSFT), and Google Cloud, making IonQ a top choice for developers building quantum applications. In Q1, IonQ posted $7.6 million in revenue and forecasted full-year revenue between $75–$95 million, nearly doubling last year's figure, while trimming losses to $0.14 per share from $0.19. The buzz lately? Their aggressive M&A strategy. IonQ recently acquired Lightsynq Technologies to accelerate the development of fault-tolerant quantum systems and invested $1 billion in Oxford Ionics to boost R&D, aiming to scale up to 2 million physical qubits by 2030. They've also forged partnerships with heavyweights such as AstraZeneca and Nvidia in quantum-powered drug discovery and secured a key contract under DARPA's Quantum Benchmarking Initiative. Yes, a $10.4 billion market cap is steep given current revenues, but the long-term thesis hinges on IonQ's strategic partnerships, cloud integration, and early mover advantage potentially paying off for investors willing to ride out the volatility. Is IonQ a Buy, Hold, or Sell? Currently, most analysts are bullish on IONQ stock. The stock features a Strong Buy consensus rating based on four Buy and one Hold ratings assigned in the past three months. No analyst rates the stock a sell. IONQ's average stock price target of $43 implies ~11% upside over the next twelve months, despite shares having already rallied about 400% since this time last year. Rigetti Computing (NASDAQ:RGTI) | The Superconducting Maverick Rigetti's story is a bit more turbulent, but still intriguing. Their superconducting gate-based systems are built for speed, executing operations in just 60–80 nanoseconds, far faster than ion-based platforms. That kind of performance is ideal for time-sensitive workloads, such as financial modeling and AI. As a vertically integrated company, Rigetti controls everything from chip design to cloud access, positioning itself for potential large-scale growth. Their 84-qubit Ankaa-3 system debuted in Q1, and they're targeting enterprise clients, including HSBC and Moody's. However, the financial picture is rough. Q1 revenue dropped 52% to $1.47 million, and the company reported a staggering $200.99 million net loss on just $10.79 million in revenue for 2023, highlighting a steep burn rate. Still, Rigetti isn't standing still. They landed a $35 million deal with Quanta Computer, secured a £3.5 million UK consortium lead focused on quantum error correction, and earned DARPA support—solid wins that keep them relevant. Looking ahead, analysts expect revenue to grow to $23 million in 2026 and $38 million in 2027. It's a high-risk play, but if execution improves, Rigetti could be at the start of a long-term turnaround. Is Rigetti Stock a Good Buy? On Wall Street, Rigetti stock carries a Strong Buy consensus rating based on five unanimous Buy ratings. No analyst rates the stock a hold or a sell. RGTI's average stock price target of $15 implies almost 24% upside potential over the next twelve months. D-Wave Quantum (NYSE:QBTS) | The Tempered All-Star D-Wave Quantum is taking a different path—and making no apologies for it. Their quantum annealing technology, designed for optimization tasks like supply chain logistics and drug discovery, is already producing real-world results. Their Advantage2 system, with over 4,400 qubits, recently completed a magnetic simulation in minutes—something a classical supercomputer would take a million years to solve, according to a Science journal paper. In Q1, revenue hit a record $15 million, a sixfold increase year-over-year, with strong momentum expected to continue. The stock has been on a tear, skyrocketing 1,281% over the past year, far outpacing IonQ's 402% and Rigetti's 840%. Their Leap cloud platform is available in 40+ countries and serves 25 Forbes Global 2000 clients, showcasing real commercial traction for quantum. But with a $5.22 billion market cap and a price-to-sales ratio nearing 200x, the valuation is steep and heavily speculative. The key question is whether D-Wave's annealing approach can hold its edge as gate-based systems advance. It's still early days, and the verdict remains uncertain—but for now, D-Wave is proving that practical quantum solutions might not be as far off as once thought. Is D-Wave a Good Stock to Buy? D-Wave is currently covered by six Wall Street analysts, all of whom hold a bullish outlook. The stock carries a Strong Buy consensus rating with all six analysts assigning a Buy rating over the past three months. However, QBTS's average price target of $13 suggests approximately 18% downside potential over the next twelve months. Why Roll the Dice? Quantum computing stocks are far from safe bets—they come with deep losses, sky-high valuations, and intense competition from tech giants like Google and IBM. Still, IonQ's enterprise-ready systems, Rigetti's speed-focused tech, and D-Wave's real-world traction make them standout players in a field with extensive long-term commercialization capacity. While the future of their revenues and profitability remains uncertain, all three deserve a spot on investor watchlists.
Business Insider
2 hours ago
- Business Insider
Senmiao Technology Stock (AIHS) Plummets 40% on Changsha Yipeng Agreement
Senmiao Technology (AIHS) stock took a beating on Friday after the financing and servicing company announced a collaboration agreement with Changsha Yipeng Information Technology. The two companies will work together to develop an artificial intelligence (AI)-backed data management system. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The system created by these two companies will be used to 'improve efficiency of online ride-hailing management platforms.' Changsha Yipeng will bring its experience creating AI management systems, while Senmiao Technology will contribute its data from the Chinese online ride-hailing industry. The two companies also intend to seek financing for the development and deployment of this system. Investors were not pleased by today's announcement, which sent shares of AIHS stock down 38.83% in pre-market trading, following a 10.43% drop yesterday. Shares of AIHS have also fallen 3.74% year-to-date. As of this writing, more than 9 million shares of AIHS have traded, compared to a three-month daily average of 1.4 million shares. Is Senmiao Technology Stock a Buy, Sell, or Hold? Wall Street doesn't have the best coverage of Senmiao Technology, but TipRanks' AI analyst Spark has it covered. Spark rates AIHS an Underperform (36) with no price target. It cites 'significant financial challenges with declining revenues and negative equity,' as reasons for the rating.
Yahoo
2 hours ago
- Yahoo
Bloom Energy's (BE) Alternative Power Play: UBS Sees Growth Ahead
Bloom Energy Corporation (NYSE:) is one of the . On June 12, UBS analyst Manav Gupta reiterated a 'Buy' rating on the stock with a $29.00 price target. The firm has reaffirmed its positive stance on the company while making minor adjustments to its quarterly estimates. It expects Bloom to report second-quarter 2025 sales of $365 million, an increase from the $326 million reported in the first quarter of 2025. It also expects improved profitability with second-quarter EBITDA forecasted to reach $35 million, up from $25 million in the previous quarter. A panoramic aerial view of a modern data center with high-performance computing. The firm projected that Bloom Energy will achieve total sales of $1,777 million for the full fiscal year 2025. All in all, the firm is bullish on the stock as Bloom continues to grow its presence in the alternative energy sector with its solid oxide fuel cell technology. Bloom Energy Corporation (NYSE:BE) develops solid-oxide fuel cell systems for on-site power generation, helping meet the growing energy demands of AI data centers. While we acknowledge the potential of BE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
